NEW YORK (GenomeWeb News) - Ciphergen Biosystems this week said it had no revenue in the first quarter of 2007, while R&D spending was down 23 percent and net loss improved by 12 percent.
 
The company also said its planned name change to Vermillion will take effect on Aug. 27, when it also will begin trading under the symbol VRML.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.